Last reviewed · How we verify
NCT05229731: NEVICOG
Description of the Neurovisual and Radiological Specificities of Patients With Visual Snow Syndrome
trial testing Neurovisual evaluation in Visual Snow Syndrome. Withdrawn.
13 April 2022
Quick facts
| Lead sponsor | Fondation Ophtalmologique Adolphe de Rothschild |
|---|---|
| Status | Withdrawn |
| Study type | OBSERVATIONAL |
| Start date | 13 April 2022 |
| Primary completion | 13 April 2022 |
| Estimated completion | 13 April 2022 |
| Sites | 1 location across France |
Drugs / interventions tested
- Neurovisual evaluation
- Cerebral MRI
Conditions studied
- Visual Snow Syndrome — all drugs for Visual Snow Syndrome →
Sponsor
Fondation Ophtalmologique Adolphe de Rothschild — full company profile →
Who can join
18 and older, any sex, with Visual Snow Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
NEVICOG is a single-center study evaluating neurovisual and radiological specificities in patients with visual snow syndrome (VSS) compared to a control population.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05229731
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Visual Snow Syndrome
Currently open trials in the same condition.
- NCT07110493 — Study of Visual Perception Phenomena: Phosphene Mapping Induced by TMS and Its Relationship With Eye Movements · NA · recruiting
- NCT06961864 — Investigating Brain Function in People With and Without Visual Snow Syndrome Using Adaptation to Visual Stimuli · NA · recruiting
- NCT05524493 — High-field MR Imaging in Migraine, Visual Snow and Epilepsy · recruiting
Other Fondation Ophtalmologique Adolphe de Rothschild trials
Trials by the same sponsor.
- NCT04701619 — Immuno-inflammatory Profile and Response to Ischemic Stroke Reperfusion Therapies (IMMUNOSTROKE) · NA · not yet recruiting
- NCT04763161 — Immuno-inflammation in the Acute Phase of an Ischaemic Cerebral Accident Managed by Decompressive Hemicraniectomy: a Cas · not yet recruiting
- NCT06264531 — Efficacy and Safety of Anti-angiogenic Therapy With IV Bevacizumab in Patients With Symptomatic Cerebral Arteriovenous M · Phase 2, PHASE3 · recruiting
- NCT06895044 — Evolution of Ocular Growth in Myopic Children: A Prospective Cohort Study · recruiting
- NCT06644196 — Creation of a Database of Images of the Eye With the Holographic Doppler Laser · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05229731 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fondation Ophtalmologique Adolphe de Rothschild
- Last refreshed: 20 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05229731.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing